A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

Am J Hematol. 2019 Nov;94(11):E291-E294. doi: 10.1002/ajh.25605. Epub 2019 Aug 20.

Authors

Benjamin K Tomlinson¹, Joseph M Tuscano², Mehrdad Abedi², Jeanna Welborn², Mili Arora², Robert T O'Donnell², Ted Wun², Brian A Jonas²

Affiliations

¹ Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio.
² Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California.

PMID: 31379016
DOI: 10.1002/ajh.25605

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Bortezomib / adverse effects
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Doxorubicin / analogs & derivatives
Febrile Neutropenia / chemically induced
Female
Humans
Hydroxyurea / administration & dosage
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Neoplastic Cells, Circulating
Polyethylene Glycols / administration & dosage
Polyethylene Glycols / adverse effects
Progression-Free Survival
Proteasome Inhibitors / administration & dosage
Proteasome Inhibitors / adverse effects
Treatment Outcome

Substances

Proteasome Inhibitors
liposomal doxorubicin
Polyethylene Glycols
Bortezomib
Doxorubicin
Hydroxyurea

Grants and funding